Omega-3 API maker KD Pharma snaps up U.K. manufacturing site for undisclosed price

Pills and vitamins
The company said the acquisition will allow it to expand capacity for producing omega-3 intermediates used in the manufacture of APIs. (Steven Depolo/CC BY 2.0)

KD Pharma, a Swiss API maker of omega-3 products, has snapped up a manufacturing site in Seal Sands, U.K., for an undisclosed price.

The company said the acquisition will allow it to expand capacity for producing omega-3 intermediates used in the manufacture of APIs. The Seal Sands facility was previously used to make omega-3 products.

KD Pharma, which employs about 400 people globally, has seven sites situated in the U.K. and U.S. The company makes omega-3 fatty acid products that are used in finished products like soft gel capsules and bottled liquid forms of pharmaceutical products.

“The acquisition expands our technology and manufacturing base for producing APIs with the highest concentrations of EPA and DHA omega-3s,” Oscar Groet, KD Pharma’s chief executive, said in a statement. “The breadth of our technology platform sets KD Pharma apart, no company has more technologies for isolating and fractionating lipids.”

The Seal Sands plant is expected to be up and running for KD Pharma by the end of the year. The company’s other sites include Bexbach, Germany, Brattvagm, Norway and Miami.

Read more on

Suggested Articles

Lonza’s search for a new CEO is expected to be wrapped up this year as the CDMO homes in on a list of veterans from outside the company.

Eli Lilly has a pipeline stuffed with a host of assets and has decided it needs a new injectable drug and device plant to manufacture some of them.

The $520 million investment includes $230 million for AZ's Dunkirk, France manufacturing site dedicated to inhalers and $275 million for R&D.